BRAF mutation testing with a rapid, fully integrated molecular diagnostics system
Metrics: PDF 1982 views | HTML 1876 views | ?
Filip Janku1,*, Bart Claes2,*, Helen J. Huang1, Gerald S. Falchook1,3, Benoit Devogelaere2,9, Mark Kockx10, Isabelle Vanden Bempt10, Martin Reijans2, Aung Naing1, Siqing Fu1, Sarina A. Piha-Paul1, David S. Hong1, Veronica R. Holley1, Apostolia M. Tsimberidou1, Vanda M. Stepanek1, Sapna P. Patel4, E. Scott Kopetz5, Vivek Subbiah1, Jennifer J. Wheler1, Ralph G. Zinner1, Daniel D. Karp1, Rajyalakshmi Luthra6, Sinchita Roy-Chowdhuri7, Erwin Sablon2, Funda Meric-Bernstam1, Geert Maertens2, Razelle Kurzrock1,8
1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Biocartis NV, 2800 Mechelen, Belgium
3Sarah Cannon Research Institute at HealthONE, Denver, CO 80218, USA
4Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
5Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
6Molecular Diagnostics Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
7Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
8Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, La Jolla, CA 92093, USA
9Cartagenia, 3001 Leuven, Belgium
10HistoGeneX NV, 2600 Berchem, Belgium
*These authors have contributed equally to this work
Filip Janku, e-mail: email@example.com
Keywords: BRAF, rapid, integrated, qPCR
Received: June 03, 2015 Accepted: July 17, 2015 Published: July 27, 2015
Fast and accurate diagnostic systems are needed for further implementation of precision therapy of BRAF-mutant and other cancers. The novel IdyllaTM BRAF Mutation Test has high sensitivity and shorter turnaround times compared to other methods. We used Idylla to detect BRAF V600 mutations in archived formalin-fixed paraffin-embedded (FFPE) tumor samples and compared these results with those obtained using the cobas 4800 BRAF V600 Mutation Test or MiSeq deep sequencing system and with those obtained by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory employing polymerase chain reaction–based sequencing, mass spectrometric detection, or next-generation sequencing. In one set of 60 FFPE tumor samples (15 with BRAF mutations per Idylla), the Idylla and cobas results had an agreement of 97%. Idylla detected BRAF V600 mutations in two additional samples. The Idylla and MiSeq results had 100% concordance. In a separate set of 100 FFPE tumor samples (64 with BRAF mutation per Idylla), the Idylla and CLIA-certified laboratory results demonstrated an agreement of 96% even though the tests were not performed simultaneously and different FFPE blocks had to be used for 9 cases. The IdyllaTM BRAF Mutation Test produced results quickly (sample to results time was about 90 minutes with about 2 minutes of hands on time) and the closed nature of the cartridge eliminates the risk of PCR contamination. In conclusion, our observations demonstrate that the Idylla test is rapid and has high concordance with other routinely used but more complex BRAF mutation–detecting tests.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.